Tivic Health Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Tivic Health Systems şirketinin toplam hissedar öz sermayesi $2.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.4M ve $560.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.19m
Eşitlik	US$2.83m
Toplam yükümlülükler	US$560.00k
Toplam varlıklar	US$3.39m

Son finansal sağlık güncellemeleri

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TIVC 'nin kısa vadeli varlıkları ( $3.2M ) kısa vadeli yükümlülüklerini ( $560.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: TIVC un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TIVC borçsuzdur.

Borcun Azaltılması: TIVC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TIVC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: TIVC un, serbest nakit akışı her yıl % 20.7 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Tivic Health Systems Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Recent updates

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin